Exabis Library
Welcome to the e-CCO Library!
P464: Assessing medication adherence in patients with inflammatory bowel disease: what do we choose, self-adherence scales or pharmacy rates?
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P464: Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P464: Rac1/pSTAT3 expression in T lymphocytes: A potential pharmacodynamic marker for thiopurines in the treatment of Inflammatory Bowel Disease patients?
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P464: Recurrence of ulcerative colitis during pregnancy in patients who became pregnant during remission
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P464: Steroid dependency in patients with Ulcerative Colitis treated with advanced therapies in a German real-world-setting
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P464: Study of the usual aetiologies of methotrexate and azathioprine discontinuation in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P464: Switching from the originator infliximab to biosimilar CT-P13 did not change the quality of life and clinical efficacy for IBD patients in stable remission in daily clinical practice (interim analysis)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P465 Therapeutic drug monitoring in Crohn’s disease patients, a comparison between homogeneous mobility shift assay and point of care method
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P465: Do infliximab trough levels differ between adult and paediatric patients with Crohn’s disease in clinical remission?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P465: Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P465: Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P465: Indication-specific feasibility assessment of a placebo-controlled randomised mesalazine withdrawal study for paediatric patients with ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P465: Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P465: One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P465: UC trial designed more than 5 years ago in the light of the EMA guideline on the development of new medicinal products for the treatment of ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P466 Is it possible avoid colectomy with rescue dual therapy with vedolizumab plus tacrolimus in ulcerative colitis that losing response to anti-tumour necrosis factor?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P466: Acetarsol is an effective and safe option in the management of refractory ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P466: Acute Severe Ulcerative Colitis in the modern era: biologic therapy-exposed patients and salvage therapy with intensified infliximab.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P466: Efficacy and safety outcomes in patients with moderate to severe ulcerative colitis stratified by ethnicity and race: a pooled analysis of data from GEMINI 1, VARSITY, and VISIBLE 1
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P466: Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM